| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d83be4e8c15d5a66eaec672e72c594c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5fdb1fd6b30849ff33ec94cc0bcef44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f43b03ef5dc485ddc91e2179b65d1608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94c76ea85c8a6bf774ea5f0c6bbd2046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43b4858ba46c95cd76898957f00c97e0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| filingDate |
2011-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70e9533b1ec94b3a0594f3aaa133721c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0fdbc67e8e6c0e22490ffe09b59e8ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_455c16683d24ebe0a4b116d664ef8561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36b3469b6b7b8206ac0ea6ec94f91ed6 |
| publicationDate |
2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012072850-A2 |
| titleOfInvention |
Compounds for treating cardiac damage after ischaemia/reperfusion |
| abstract |
The present invention relates to the use of an EMMPRIN inhibitor for preventing and/or treating cardiac damage arising after an ischaemic process followed by reperfusion. The authors of the present invention have observed that EMMPRIN expression is raised in individuals who have suffered ischaemia/reperfusion, ascertaining that an EMMPRIN inhibitor is capable of reducing the cardiac damage caused after ischaemia followed by reperfusion, not only in vitro but also in vivo . |
| priorityDate |
2010-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |